Home LiteratureArticle Details
PMID: 21633392 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Developing therapeutic microRNAs for cancer.

Gene therapy ·Vol. 18 ·No. 12 ·2011-12-00 ·Pages 1121-6

Bader AG, Brown D, Stoudemire J, Lammers P

Abstract

Despite substantial progress in understanding the cancer-signaling network, effective therapies remain scarce due to insufficient disruption of oncogenic pathways, drug resistance and drug-induced toxicity. This complexity of cancer defines an urgent goal for researchers and clinicians to develop novel therapeutic strategies. The discovery of microRNAs (miRNAs) provides new hope for accomplishing this task. Supported by solid evidence for a critical role in cancer and bolstered by a unique mechanism of action, miRNAs are likely to yield a new class of targeted therapeutics. In contrast to current cancer medicines, miRNA-based therapies function by subtle repression of gene expression on a yet large number of oncogenic factors and are, therefore, anticipated to be highly efficacious. After the completion of target validation for several candidates, the development of therapeutic miRNAs is now moving to a new stage that involves pharmacological drug delivery, preclinical toxicology and regulatory guidelines.

MeSH Terms
Drug Evaluation, Preclinical Gene Targeting Guidelines as Topic Humans MicroRNAs/administration & dosage,antagonists & inhibitors,therapeutic use Molecular Targeted Therapy Neoplasms/therapy
Chemicals
MicroRNAs
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bader A G
Mirna Therapeutics, Inc., Austin, TX 78744, USA. abader@mirnarx.com
Brown D
Stoudemire J
Lammers P
References (46)
46 references, click to expand
  1. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.
    Nature. 2007 Oct 11;449(7163):682-8 PMID: 17898713
  2. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
    Nat Med. 2011 Feb;17(2):211-5 PMID: 21240262
  3. let-7 regulates self renewal and tumorigenicity of breast cancer cells.
    Cell. 2007 Dec 14;131(6):1109-23 PMID: 18083101
  4. The promises and pitfalls of RNA-interference-based therapeutics.
    Nature. 2009 Jan 22;457(7228):426-33 PMID: 19158789
  5. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.
    Nature. 2008 Apr 3;452(7187):591-7 PMID: 18368052
  6. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing.
    RNA. 2004 Mar;10(3):544-50 PMID: 14970398
  7. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy.
    Cancer Res. 2007 Dec 1;67(23):11111-6 PMID: 18056433
  8. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a.
    J Proteome Res. 2011 Feb 4;10(2):479-87 PMID: 21182263
  9. Liposomal cancer therapy: exploiting tumor characteristics.
    Expert Opin Drug Deliv. 2010 Feb;7(2):225-43 PMID: 20095944
  10. The promise of microRNA replacement therapy.
    Cancer Res. 2010 Sep 15;70(18):7027-30 PMID: 20807816
  11. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
    Nature. 2010 Apr 15;464(7291):1067-70 PMID: 20305636
  12. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
    Science. 2010 Jan 8;327(5962):198-201 PMID: 19965718
  13. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.
    Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12177-82 PMID: 16091473
  14. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.
    Cell Metab. 2006 Feb;3(2):87-98 PMID: 16459310
  15. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model.
    Nat Biotechnol. 2010 Apr;28(4):341-7 PMID: 20351690
  16. Development trends for new cancer therapeutics and vaccines.
    Drug Discov Today. 2008 Jan;13(1-2):30-7 PMID: 18190861
  17. Nanoparticle therapeutics: an emerging treatment modality for cancer.
    Nat Rev Drug Discov. 2008 Sep;7(9):771-82 PMID: 18758474
  18. Silencing of microRNAs in vivo with 'antagomirs'.
    Nature. 2005 Dec 1;438(7068):685-9 PMID: 16258535
  19. An integrated genomic analysis of human glioblastoma multiforme.
    Science. 2008 Sep 26;321(5897):1807-12 PMID: 18772396
  20. Knocking down barriers: advances in siRNA delivery.
    Nat Rev Drug Discov. 2009 Feb;8(2):129-38 PMID: 19180106
  21. RAS is regulated by the let-7 microRNA family.
    Cell. 2005 Mar 11;120(5):635-47 PMID: 15766527
  22. LNA-modified oligonucleotides mediate specific inhibition of microRNA function.
    Gene. 2006 May 10;372:137-41 PMID: 16503100
  23. Oncomirs - microRNAs with a role in cancer.
    Nat Rev Cancer. 2006 Apr;6(4):259-69 PMID: 16557279
  24. Adenovirus p53 gene therapy.
    Expert Opin Biol Ther. 2006 Jan;6(1):55-61 PMID: 16370914
  25. MicroRNA silencing in primates: towards development of novel therapeutics.
    Cancer Res. 2009 Jan 15;69(2):393-5 PMID: 19147547
  26. miR-34a repression of SIRT1 regulates apoptosis.
    Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13421-6 PMID: 18755897
  27. Cancer complexity slows quest for cure.
    Nature. 2008 Sep 11;455(7210):148 PMID: 18784686
  28. The let-7 microRNA reduces tumor growth in mouse models of lung cancer.
    Cell Cycle. 2008 Mar 15;7(6):759-64 PMID: 18344688
  29. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.
    Mol Ther. 2010 Jan;18(1):181-7 PMID: 19738602
  30. Sequence-specific inhibition of small RNA function.
    PLoS Biol. 2004 Apr;2(4):E98 PMID: 15024405
  31. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi.
    Cell. 2002 Sep 6;110(5):563-74 PMID: 12230974
  32. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.
    Cell. 2004 Jun 25;117(7):927-39 PMID: 15210113
  33. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.
    Cell. 2009 Jun 12;137(6):1005-17 PMID: 19524505
  34. Asymmetry in the assembly of the RNAi enzyme complex.
    Cell. 2003 Oct 17;115(2):199-208 PMID: 14567917
  35. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.
    Genes Dev. 2001 Dec 15;15(24):3243-8 PMID: 11751630
  36. A microRNA component of the p53 tumour suppressor network.
    Nature. 2007 Jun 28;447(7148):1130-4 PMID: 17554337
  37. Nonviral delivery of synthetic siRNAs in vivo.
    J Clin Invest. 2007 Dec;117(12):3623-32 PMID: 18060020
  38. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses.
    J Immunol. 2008 Mar 15;180(6):3729-38 PMID: 18322178
  39. MicroRNAs: genomics, biogenesis, mechanism, and function.
    Cell. 2004 Jan 23;116(2):281-97 PMID: 14744438
  40. LNA-mediated microRNA silencing in non-human primates.
    Nature. 2008 Apr 17;452(7189):896-9 PMID: 18368051
  41. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells.
    PLoS One. 2009 Aug 28;4(8):e6816 PMID: 19714243
  42. MicroRNA signatures in human cancers.
    Nat Rev Cancer. 2006 Nov;6(11):857-66 PMID: 17060945
  43. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  44. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.
    Nature. 2010 Sep 2;467(7311):86-90 PMID: 20693987
  45. Regression of murine lung tumors by the let-7 microRNA.
    Oncogene. 2010 Mar 18;29(11):1580-7 PMID: 19966857
  46. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
    Cancer Res. 2010 Jul 15;70(14):5923-30 PMID: 20570894
Article Info
Journal
Gene therapy
Abbr.
Gene Ther
ISSN
1476-5462
DOI
10.1038/gt.2011.79
Email
abader@mirnarx.com
Published
2011-12-00
Epub
2011-00-02
Pages
1121-6
Language
English
Region
England
NLM ID
9421525
PMCID
PMC3910432
Subset
IM
Grants
NCI NIH HHS · R43 CA134071 · United States
NCI NIH HHS · R43 CA137939 · United States
NCI NIH HHS · 1R43CA134071 · United States
NCI NIH HHS · 1R43CA137939 · United States
External Links
PubMed source DOI: 10.1038/gt.2011.79 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2